Delivering the promise of public health genomics
Can genomics help developing countries face their growing burden of disease?Since the completion of the human genome project in 2003, scientific activities that were unheard-of a decade ago, such as sequencing the genes of a newly emerging virus in days, the ability to screen for inherited diseases and the potential for personalised medicine have all become a part of public health landscape.Genomics is often associated with the detection of single gene disorders, such as thalassemia and sickle cell anaemia. Momentum is growing for developing countries to harness such technology, but the utility of genomic research is far wider than that: it has the potential to help them tackle the double burden of infectious and non-infectious diseases.Examples of current research include using genomics to analyse disease outbreaks, examine antibiotic susceptibility and resistance to drugs and identify genetic risk factors for breast cancer. "Genomics is absolutely changing the way we deal with public health issues and as the technology involves gets a lot cheaper, there will be a massive shift in diagnostics towards molecular technology," said Hilary Burton, director of the Cambridge-based PHG Foundation."The problem is that the companies developing pharmaceuticals and diagnostic tests will be more interested in the high-income countries, and it may be hard to get the right focus in terms of the spectrum of conditions people are exposed to. We can expect a lot of developments...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: Available online 10 October 2020Source: Journal of Genetics and GenomicsAuthor(s): Chengqi Wang, Justin Gibbons, Swamy R. Adapa, Jenna Oberstaller, Xiangyun Liao, Min Zhang, John H. Adams, Rays H.Y. Jiang
Publication date: Available online 9 October 2020Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Klaudia Kulczynska-Figurny, James J. Bieker, Miroslawa Siatecka
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Ibironke W. Apata, Sarah Kabbani, Alicia M. Neu, Tamara M. Kear, Erika M.C. D’Agata, David J. Levenson, Alan S. Kliger, Lauri A. Hicks, Priti R. Patel, authors constitute the ASN and CDC Antibiotic Stewardship White Paper Writing Group
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
More News: Anemia | Blindness | Blogging | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Dialysis | Eating Disorders & Weight Management | Endocrinology | Environmental Health | Epidemics | Epidemiology | Forensic Medicine | Funding | Genetics | Government | Health | Health Management | Heart | Heart Disease | Infectious Diseases | International Medicine & Public Health | Legislation | Malaria | Medical Ethics | National Institutes of Health (NIH) | Obesity | Opthalmology | Outbreaks | Politics | Research | Science | Sickle Cell Anemia | Urology & Nephrology